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OBJECTIVE: This study was designed to: 1) identify in-
dividuals with and without a claims diagnosis for depres-
sion who received new prescriptions for SSRI antidepres-
sants, and 2) describe SSRI usage patterns in those with
depression.
METHODS: This was a retrospective database claims
analysis. Medical and pharmacy claims records of pa-
tients 18–64 years from 13 United Health–affiliated
health plans were examined from 1/1/93 to 12/31/97. Pa-
tients had a 6-month SSRI-free period before the index
SSRI prescription; their claims were examined in the 6
months after their index prescription. They were identi-
fied as having an ICD-9 claims diagnosis for depression
or not. Results were adjusted using logistic regression.
RESULTS: Of 46,139 patients, 22,693 (49.1%) had a
depression diagnosis, 6515 (14.1%) for major depres-
sion. A lower proportion of patients with major depres-
sion diagnoses (18.5%) achieved stable SSRI therapy
(150 days) than did those with all depression diagnoses
(21%). However, a higher proportion of patients with
major depression diagnoses had their therapy switched,
augmented or titrated (34.8% versus 26.8%). Paroxetine
users (OR  0.53; 95% CI 0.44–0.64) and sertraline us-
ers (OR  0.59; 95% CI 0.48–0.73) were less likely to
achieve stable therapy relative to fluoxetine users. They
were also less likely to have their SSRI therapy aug-
mented (OR  0.84; 95% CI 0.73–0.96 and OR  0.84;
95% CI 0.72–0.99, respectively) but more likely to
switch therapy (OR  1.69; 95% CI 1.49–1.92 and
OR  1.32; 95% CI 1.14–1.52).
CONCLUSIONS: Approximately half the study subjects
had no diagnosis for depression. Patients with major de-
pression diagnoses received more alterations in therapy
than those with all depression diagnoses. Fluoxetine
treatment resulted in greater duration of therapy and less
switching.
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OBJECTIVE: To compare continuation rates of fluoxe-
tine and sertraline for treatment of depression in poor,
young women, a particularly high-risk subgroup.
METHODS: A cohort was identified using Ohio Medi-
caid claims data for 7/1/91 to 6/30/96. Patients were con-
tinuously enrolled 1 year prior until 1 year following in-
dex Rx. Included were females aged 25–44, diagnosis of
depression 30 days prior to index Rx. Patients were ex-
cluded if they had other mood disorders, were disabled,
were prescribed any antidepressant in the last year, or in-
dex Rx was prescribed by a mental health specialist. Pre-
scriptions were for 	30 days, without co-pays. Age, race-
adjusted multivariate regression models (ordinary, logistic)
were fit, stratified by depression type (single episode, re-
current). Outcome variables were: 1) short-term success,
defined as filling three consecutive Rxs for the same drug,
with the first two Rxs totaling 
30 days at usual starting
levels (20 mg fluoxetine, 50 mg sertraline), and 2) long-
term success, measured as the number of prescriptions
filled for the same drug in the following year, among
those classified as short-term success.
RESULTS: Sample size was 333: 182 fluoxetine, 151 ser-
traline. Recurrent depression accounted for 44% of
cases. Drug choice was similar for both depression types.
Assuming 30-day Rxs, average daily dose was compara-
ble to that found in surveillance studies. Multivariate
models produced conflicting results for the two depres-
sion types. In single depression, sertraline had fewer short-
term successes (OR  0.496; 95% CI 0.272–0.901]), with
no statistically significant difference in long-term success.
In recurrent depression, although there was no difference
in short-term success, sertraline users filled 2.6 additional
prescriptions in the coming year (p  0.02).
CONCLUSION: Fluoxetine had better short-term contin-
uation rates in single-episode depression, sertraline had
better long-term continuation in recurrent depression.
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Depression has an impact on social functioning which may
lead to a decrease in work productivity by affected individ-
uals. Selective serotonin reuptake inhibitors (SSRIs) such
as fluoxetine are commonly used to treat patients with this
disorder. However, reboxetine, one of the first in the new
class of non-tricyclic selective noradrenaline reuptake in-
hibitors (NRIs), may lead to improved social functioning
due to noradrenaline’s effect on motivation.
OBJECTIVE: The purpose of this analysis was to evalu-
ate the effect of reboxetine relative to fluoxetine in regard
to social functioning, as measured by a validated 21-item
self rating scale, the Social Adaptation Self Evaluation
Scale (SASS).
METHODS: A model using longitudinal patient data
from two 8-week clinical trials was developed using a
mixed-model analysis of variance approach. Using data
from 282 depressed patients, this model depicts the per-
centage change from baseline SASS score as a function of
both time-invariant and time-varying covariates, con-
founding variables, and covariate interactions. Time-
varying covariates include the percentage change from
baseline Hamilton Depression scale score (HAM-D), and
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measures from the Clinical Global Impression scale. Ad-
ditional variables include relevant demographic and dis-
ease characteristics.
RESULTS: Depressed patients treated with reboxetine
have a greater increase in SASS score from baseline rela-
tive to those treated with fluoxetine. We found that this
increased effect of reboxetine depends on both the pa-
tient’s clinical severity and measurement time. We also
found a significant association between the percentage
change from baseline HAM-D score and the percentage
change from baseline SASS score.
CONCLUSIONS: Our results suggest that, after control-
ling for patient characteristics and measures of depres-
sion severity, reboxetine is more effective than fluoxetine
at increasing overall social functioning as measured by
the SASS.
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OBJECTIVE: The purpose of this study was to evaluate,
from the perspective of California’s Medicaid program
(Medi-Cal), the policy decision to include fluoxetine on
its formulary. The analysis includes a review of the for-
mulary adoption process, financial inducement, and data
presented to the Medi-Cal program.
METHODS: The time horizon for this analysis extends
from 1996 to 2004 (the date of formulary inclusion until
patent expiration). Using 1994–1997 values as a base-
line, calculation of the incremental Net Present Value in-
volved projecting fluoxetine’s acquisition price, phar-
macy dispensing fee, manufacturer’s rebate, treatment
authorization costs, CPI for prescription drugs and medi-
cal care, number of eligibles enrolled in Medi-Cal fee-for-
service, fee-for-service eligibles to be transferred into
managed care, population projections, and cost of inten-
tion to treat with fluoxetine (which included treatment
failures). The net savings in cost-of-care per patient of
$3524 (1994 US dollars, p  0.0024) was provided by
previous research. The annual discount rate employed
was 5.707%, the FY 1996–1997 rate for the Pooled
Money Investment Account (the state’s general funding
for Medi-Cal).
RESULTS: The model yielded a Net Present Value for flu-
oxetine formulary inclusion, which resulted in estimated
savings to the State of between $1.025 and $1.760 billion
over the 8-year time frame. The sensitivity analysis in-
volved varying the projected number of fee-for-service eli-
gibles to be transferred into contracted managed care.
CONCLUSION: The potential savings to be derived from
the appropriate treatment of persons suffering from major
depressive disorder are socially and economically signifi-
cant. More emphasis should be placed on the appropriate
pharmacotherapy of major depressive disorder, since the
drug acquisition costs are minimal in comparison to the
associated healthcare and indirect societal costs.
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Diabetes is a common risk factor for cardiovascular dis-
ease. Depression is associated with cardiovascular disease
and may negatively impact overall management.
OBJECTIVE: The objective of this study was to docu-
ment the presence of cardiovascular risk factors (diabetes
mellitus, hypertension, and hyperlipidemia) and the phar-
macotherapeutic management of these conditions in pri-
mary care patients receiving antidepressant medications.
METHODS: The electronic medical records (EMR) of
primary care patients at an academic medical center were
evaluated for the above clinical conditions and medica-
tions. Only patients prescribed an antidepressant drug
within the previous 6 months were reviewed, in the order
in which they were entered into the EMR system.
RESULTS: The electronic records of 115 patients receiv-
ing antidepressant drugs were reviewed by two physician
researchers. Data for 88 (76.5%) female and 27 (23.5%)
male patients were evaluated. The mean age for these pa-
tients was 46.5 years. Sixty-one (53.0%) patients were
white, 38 (33.0%) were black. Twenty-one (18.3%) pa-
tients had diabetes, 56 (48.7%) had hypertension, and 14
(12.2%) had hyperlipidemia. Of special significance was
that 20 of 21 (95.2%) patients with diabetes also had hy-
pertension. In addition to cardiovascular risks, 13 (11.2%)
had developed coronary artery disease with an additional
3 (2.6%) patients having had myocardial infarction. The
mean number of prescriptions for 58 patients without dia-
betes and hypertension was 2.1 while the mean for 20 pa-
tients with diabetes and hypertension was 7.0.
CONCLUSIONS: The link between cardiovascular risk
and antidepressant drug use seems to be strong. Clini-
cians should emphasize the management of cardiovascu-
lar risk factors in these patients.
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